{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-165297","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.869548+00:00","generated_at":"2026-05-15T05:08:11.782712+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Erasca narrows ERAS-0015 Phase 1 data readout timeline to mid-May 2026","bullets":["Narrowed Phase 1 monotherapy data readout for pan-RAS molecular glue ERAS-0015 to no later than mid-May 2026 (prior: first half 2026).","Data from two trials: Erasca's AURORAS-1 (RAS-mutant solid tumors) and Joyo's JYP0015M101 (China, specific RAS mutations).","No financial or regulatory update; no safety or efficacy data disclosed yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-165297","json":"https://secwatch.observer/filing/0001193125-26-165297.json","markdown":"https://secwatch.observer/filing/0001193125-26-165297.md","text":"https://secwatch.observer/filing/0001193125-26-165297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526165297/0001193125-26-165297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526165297/eras-20260421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:08:11.782712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}